Skip to Content
  • Title
    CEO
  • Affiliation
    Merck

It’s easy to forget that last August, after President Trump’s tepid response to a white nationalist rally that turned violent, outcry from the business community was not immediate. Frazier took a risk by becoming the first of Trump’s advisers to speak out and step down, enabling others to follow suit. His success at Merck only bolsters his credibility: Since he took over in 2011, the pharma giant has made strides in treating several cancers, while its stock beat the S&P 500.

Fortune Data StoreLooking for leads, investment insights, or competitive intelligence?Get Premium Access